

# Pathogenic Huntingtin Inhibits Fast Axonal Transport by Activating JNK3 and Phosphorylating Kinesin

Gerardo A Morfini<sup>1,2</sup>, Yi-Mei You<sup>1</sup>, Sarah L Pollema<sup>1,2</sup>, Agnieszka Kaminska<sup>1</sup>, Katherine Liu<sup>2</sup>, Katsuji Yoshioka<sup>3</sup>, Benny Björklom<sup>4</sup>, Eleanor T. Coffey<sup>4</sup>, Carolina Bagnato<sup>5</sup>, David Han<sup>5</sup>, Chun-Fang Huang<sup>6</sup>, Gary Banker<sup>6</sup>, Gustavo Pigino<sup>1,2</sup> and Scott T. Brady<sup>1,2</sup>

<sup>1</sup>Dept. of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, USA.

<sup>2</sup>Marine Biological Laboratory, Woods Hole, MA 02543, USA.

<sup>3</sup>Division of Molecular Cell Signaling, Cancer Research Institute, Kanazawa University, Japan

<sup>4</sup>Turku Centre for Biotechnology, Åbo Akademi and Turku University, Turku, Finland.

<sup>5</sup>Center for Vascular Biology, University of Connecticut, Farmington, CT 06030, USA.

<sup>6</sup>The Jungers Center for Neurosciences Research, Oregon Health & Science University, Portland, OR 97239, USA

Send correspondence to:

Dr. Gerardo Morfini

University of Illinois at Chicago

Dept. of Anatomy and Cell Biology MC512

909 S Wolcott St. COMRB Room 6051

Chicago, IL 60612

Phone: (312) 996-6869

FAX: (312) 413-0354

Email: gmorfini@uic.edu

Dr. Scott Brady

University Of Illinois at Chicago

Dept. of Anatomy and Cell Biology MC512

808 S Wood St Room 578

Chicago, IL 60612 USA

Phone (312) 996-6869

Fax (312) 413-0354

Email: stbrady@uic.edu

8 Figures + 4 Supplemental Figures, 0 Tables, 32 Pages

**Acknowledgements:** The authors would like to thank Drs Marcy MacDonald and Marian DiFiglia for knock-in mice and huntingtin constructs, respectively, and Bin Wang for excellent technical assistance. This work was supported by 2007/2008 MBL summer fellowship to GM; an HDSA grant to GM; NIH grants MH066179 to GB; and ALSA, Muscular Dystrophy Association, and NIH (NS23868, NS23320, NS41170) grants to STB.

**Keywords.** Huntingtin, Huntington's disease, conventional kinesin, kinesin-1, JNK, JNK3, axonal transport, neurodegeneration.

**Abstract (150 words):**

Selected vulnerability of neurons in Huntington's disease (HD) suggests alterations in a cellular process particularly critical for neuronal function. Supporting this idea, pathogenic Htt (polyQ-Htt) inhibits fast axonal transport (FAT) in various cellular and animal HD models (mouse and squid), but the molecular basis of this effect remains unknown. Here we show that polyQ-Htt inhibits FAT through a mechanism involving activation of axonal JNK. Accordingly, increased activation of JNK was observed *in vivo* in cellular and animal HD models. Additional experiments indicate that polyQ-Htt effects on FAT are mediated by the neuron-specific JNK3, and not ubiquitously expressed JNK1, providing a molecular basis for neuron-specific pathology in HD. Mass spectrometry identified a residue in the kinesin-1 motor domain phosphorylated by JNK3, and this modification reduces kinesin-1 binding to microtubules. These data identify JNK3 as a critical mediator of polyQ-Htt toxicity and provides a molecular basis for polyQ-Htt-induced inhibition of FAT.

Huntington's disease (HD) is an autosomal dominant, adult-onset neurodegenerative disease<sup>1</sup>. Patients with a single mutant huntingtin (Htt) gene develop symptoms in midlife with 100% penetrance. The mutation is a toxic gain of function, because loss of a single gene has no phenotype and the Htt-null is embryonic lethal<sup>2</sup>. The disease-causing mutation is expansion of a CAG trinucleotide repeat encoding a polyglutamine (polyQ) tract and polyQ-expansions in other genes may also lead to adult-onset neurodegeneration, but pathogenic mechanisms remained uncertain<sup>2</sup>. Several lines of evidence indicated that pathogenesis in Huntington's disease include inhibition of fast axonal transport (FAT)<sup>3</sup>. Although consequences of FAT inhibition in neurons are well established, mechanisms underlying inhibition of FAT by pathogenic Htt (polyQ-Htt) were unknown. Proposed mechanisms included wild-type Htt (WT-Htt) loss of function<sup>4</sup>, physical blockade by polyQ-Htt aggregates<sup>5,6</sup>, sequestration of motor molecules<sup>4,6</sup>, and misregulation of FAT<sup>3,7,8</sup>.

We found no evidence for direct interactions of conventional kinesin and cytoplasmic dynein (CDyn) with WT-Htt or polyQ-Htt *in vivo*. However, analysis of HD models showed that polyQ-Htt, but not WT-Htt increased cJun N-terminal kinase (JNK) activity. Pharmacological and peptide inhibitors of JNK prevented inhibition of FAT by polyQ-Htt. Surprisingly, only a subset of JNK isoforms inhibited FAT, with neuron-specific JNK3 selectively mimicking effects of polyQ-Htt. *In vitro* phosphorylation and mass spectrometry studies showed that JNK3, but not ubiquitously expressed JNK1, phosphorylated Ser176 in the kinesin heavy chain (kinesin-1, KHC) motor domain. Consistent with this location, phosphorylation of kinesin-1 by JNK3 inhibited kinesin binding to microtubules and translocation along axons. Our data indicate that polyQ-Htt inhibits FAT by a mechanism involving axonal JNK3 activation and phosphorylation of kinesin-1.

## **RESULTS:**

***Htt does not interact with microtubule-based motors.*** PolyQ-Htt inhibits FAT in various experimental systems, including *Drosophila*<sup>4,5</sup>, neuroblastoma cells<sup>9,10</sup>, and isolated squid axoplasm<sup>8</sup>, but the molecular basis of inhibition was undetermined<sup>3</sup>. Interactions have been reported between exogenously overexpressed Htt and conventional kinesin<sup>4</sup> or various subunits of cytoplasmic dynein (CDyn)<sup>9-11</sup>. Alternatively, polyQ-expansion was proposed to affect Htt function as a scaffolding protein for molecular motors<sup>9,12</sup>. However, interactions between endogenous WT-Htt and molecular motors were not evaluated. We tested interactions by immunoprecipitation and subcellular fractionation (**Fig. 1**), as previously described<sup>13,14</sup>. To avoid overexpression-related artifacts, we used brain tissue from 14 month-old homozygous Hdh<sup>Q109</sup> knock-in mice and age-matched controls, which express polyQ-Htt or WT-Htt at endogenous levels<sup>15</sup>. At this age, both polyQ-Htt-derived nuclear inclusions and insoluble aggregates are found in the brains of Hdh<sup>Q109</sup> knock-in mice<sup>15</sup>. Conventional kinesin is a heterotetramer composed of two heavy chains (kinesin-1, KHC) and two light chains (KLC)<sup>13</sup>. Antibodies recognizing kinesin-1 (H2) effectively immunoprecipitated kinesin-1 from detergent-soluble brain lysates independent of genotype (**Fig. 1A**). Kinesin-1 antibodies co-immunoprecipitated KLCs<sup>13,14</sup>, but failed to co-immunoprecipitate either WT-Htt or polyQ-Htt. Similarly, antibodies against DIC co-immunoprecipitated DHC<sup>16</sup>, but did not immunoprecipitate WT-Htt or polyQ-Htt (**Fig. 1A**). Conversely, anti-Htt antibodies immunoprecipitated Htt from both wild type and homozygous Hdh<sup>Q109</sup> knock-in mouse brain lysates, but no kinesin-1, KLC, DIC nor DHC could be detected in Htt immunoprecipitates. To detect substoichiometric amounts of Htt associated with conventional kinesin or CDyn, we performed three rounds of immunoprecipitation, sufficient to nearly deplete mouse brain lysates of kinesin-1 (**Fig. 1B**) or DIC (**Supplemental Fig. 1B**). As in previous studies, marked reductions in

kinesin-1 and KLC levels occurred with each immunoprecipitation cycle<sup>13, 14</sup>. However, Htt levels remained unchanged after three immunoprecipitation cycles, regardless of genotype.

PolyQ-Htt was reported to sequester molecular motors in detergent-insoluble aggregates when overexpressed<sup>4, 6</sup>. To evaluate this at endogenous levels, brain lysates from wild type and homozygous Hdh<sup>Q109</sup> knock-in mice were fractionated into detergent-soluble and insoluble fractions, and partitioning of Htt and molecular motors analyzed by immunoblot (**Supplemental Fig. 1**). WT-Htt and polyQ-Htt levels were comparable in detergent soluble and insoluble fractions, but the bulk of kinesin-1, DHC and DIC were detergent-soluble. Molecular motor levels were similar for wild type and homozygous Hdh<sup>Q109</sup> knock-in mice. Thus, WT-Htt and polyQ-Htt expressed at endogenous levels do not interact with molecular motors; so FAT inhibition associated with polyQ-Htt must result from a different mechanism.

***JNK activity mediates FAT defects induced by polyQ-Htt.*** Effects of WT-Htt and polyQ-Htt on FAT were assayed in isolated squid axoplasm<sup>8</sup>. Perfusion of WT-Htt showed no effect (**Fig. 2A**), but perfusion of polyQ-Htt at a concentration 100-1000 times lower than kinesin-1<sup>3, 8</sup> dramatically inhibited both anterograde (kinesin-dependent) and retrograde (CDyn-dependent) FAT (**Fig. 2B**). In axoplasm, anterograde FAT of membrane-bounded organelles (MBOs) depends primarily upon conventional kinesin<sup>17</sup>, which is regulated by phosphorylation<sup>7, 18, 19</sup>. Multiple kinase activities may be deregulated in Huntington's disease<sup>20-22</sup> and inhibition of FAT by pathogenic androgen receptor (polyQ-AR) depends on JNK activation in axoplasm<sup>7</sup>. This led us to evaluate the role of JNK in polyQ-Htt-induced inhibition of FAT. Axoplasmic JNK activity was assessed *in vitro* using recombinant GST-cJun, a well-characterized JNK substrate<sup>23</sup> (**Fig. 2C**). Incubation with axoplasm lysates produced a time-dependent increase in cJun phosphorylation at JNK sites (serines 63/73), reflecting basal JNK activity in axoplasm. Pharmacological properties of endogenous axoplasmic JNK were validated with two JNK inhibitors (SP600125 and JIP peptide)<sup>23</sup>. SP600125 is a

pharmacological inhibitor of JNK, showing >20-fold selectivity for JNK over a range of kinases<sup>24</sup>.

JIP peptide (JNK inhibitor I) is a 20-amino acid peptide derived from a JNK-binding protein, which selectively inhibits JNK, but not p38 activity<sup>25</sup>. Both SP600125 and JIP peptide dramatically inhibited cJun phosphorylation, suggesting common pharmacological properties between squid and mammalian JNKs (**Fig. 2C**).

As with polyQ-AR<sup>7</sup>, co-perfusion of axoplasm with polyQ-Htt and either SP600125 (500nM, **Fig. 2D**) or JIP peptide (100 nM, **Fig. 2E**) blocked effects of polyQ-Htt on FAT, suggesting that polyQ-Htt inhibition of FAT requires JNK activity. In cultured cells, pharmacological inhibitors of histone deacetylase (HDAC) were reported to rescue defects in FAT induced by polyQ-Htt by increasing tubulin acetylation<sup>26</sup>. However, coperfusion of polyQ-Htt with the HDAC6 inhibitor BC-6-25 (10 $\mu$ M) (Compound 2<sup>27</sup>) did not prevent inhibition of FAT by polyQ-Htt in axoplasm (**Fig. 2F**). Thus, inhibition of FAT by polyQ-Htt involves activation of endogenous axonal JNK.

***PolyQ-Htt expression increases JNK activity.*** Vesicle motility and biochemical assays indicated that JNK activity mediates polyQ-Htt inhibition of FAT. JNK activation involves phosphorylation by upstream mitogen-activated protein kinase kinases (MKKs, typically MKK4/MKK7)<sup>28</sup>. Effects of polyQ-Htt on JNK phosphorylation were evaluated in cellular and animal Huntington's models, using antibodies against total JNK (pan-JNK, phosphorylation-independent) or against phosphorylated, catalytically active JNKs (pJNK). Effects of polyQ-Htt expression on JNK activation were evaluated qualitatively after transient transfection (**Fig. 3A**). NSC34 neuroblastoma cells were transfected with WT-Htt (Q18) or polyQ-Htt (Q56)<sup>29</sup>. Immunoblots show exogenous Htt constructs were expressed at levels similar to endogenous Htt. Pan-JNK and pJNK antibodies recognized two major immunoreactive bands (p46 and p54) corresponding to mammalian JNKs in NSC34 cell lysates and striatal mouse tissue (**Fig. 3A, C**)<sup>30</sup>. Expression levels for both pan-JNK immunoreactive bands were comparable in cells expressing WT-Htt and polyQ-Htt. However,

pJNK antibodies showed a clear increase in p54 immunoreactivity in cells expressing polyQ-Htt (**Fig. 3A**), consistent with previous reports<sup>20, 22, 31</sup>.

Differential activation of p54 and p46 JNKs led us to evaluate their identity using antibodies selective for JNK1, JNK2 and JNK3. Specificity was validated by immunoblotting against recombinant GST-tagged JNKs, as well as brain lysates from mice with ablation of individual JNK genes<sup>30</sup> (**Fig. 3B**). Anti-JNK1, 2 and 3 antibodies selectively recognized their target JNK (**Fig. 3B**), showing no immunoreactivity against brain lysates from mice deleted for that JNK gene (**Fig. 3B**).

We examined JNK expression in striatal tissue from 8 month-old wild-type, heterozygous and homozygous Hdh<sup>Q109</sup> mice (**Fig. 3C**). Hdh<sup>Q109</sup> knock-in mice are asymptomatic at this age<sup>15</sup>.

Phosphorylation of Akt at Ser473 was not affected (**Fig. 3C**) and pan-JNK immunoreactivity was comparable, regardless of genotype. However, pJNK immunoreactivity was significantly greater in lysates from heterozygous and homozygous Hdh<sup>Q109</sup> knock-in mice, relative to wild-type (**Fig. 3C**). Cortical lysates gave similar results (data not shown). P54 and p46 were differentially activated as observed in transfected cells. P54 showed greater increases in pJNK immunoreactivity than p46 in Hdh<sup>Q109</sup> mice relative to wild type in both striatum (**Fig. 3E**) and cortex (not shown). Consistent with autosomal dominance of HD, JNK activation increased in both heterozygous and homozygous Hdh<sup>Q109</sup> mice, but activation was greater in homozygotes than heterozygotes.

Immunoreactivity corresponding to p54 and p46 in NSC34 and striatal lysates mainly corresponded to JNK2/3 and JNK1, respectively (**Fig. 3D**). An activation ratio (**Fig. 3E**) was defined as the ratio of pJNK/JNK immunoreactivities for JNK1 (p46) or JNK2/3 (p54). Both JNK1 and JNK2/3 activation ratios were elevated in heterozygotes and homozygotes relative to wild-type brain. JNK1 activity in wild-type mice was  $1.097 \pm 0.146$  (mean  $\pm$  SEM), whereas JNK1 activity was  $1.527 \pm 0.061$  in homozygotes and  $1.342 \pm 0.133$  in heterozygotes Hdh<sup>Q109</sup> mice (n = 4 in all cases).

Differences in JNK1 activity between wild-type and Hdh<sup>Q109</sup> homozygotes was significant at  $p \leq 0.05$

in a pooled t-test, but failed to reach significance between wild-type and Hdh<sup>Q109</sup> heterozygotes.

JNK2/3 activity for wild-type mice was 0.242±0.012 (mean ± SEM), whereas JNK2/3 activity was 0.590±0.055 for homozygotes and 0.440±0.035 for heterozygotes (n = 4 in all cases). JNK2/3 activity increased in both homozygote and heterozygote Hdh<sup>Q109</sup> mice relative to WT mice and differences were significant at p≤0.01 in a pooled t-test. Both JNK1 and JNK2/3 activities were increased by polyQ-Htt, but polyQ-Htt had a greater effect on JNK2/3 than JNK1.

***JNK3 mediates effects of polyQ-Htt on FAT.*** JNK2/3 is selectively activated in neurons by stress in the presence of constitutive JNK1 activity<sup>32,33</sup>. Based on differential activation of JNKs (**Fig. 3A–B**), effects of specific JNK isoforms on FAT were evaluated. SB203580 differentially affects JNK1 and JNK2/3 *in vitro*<sup>24</sup>. At 10μM concentration, SB203580 preferentially inhibits JNK2/3; JNK1 inhibition requires a 10-fold higher concentration<sup>23</sup>. Axoplasmic JNK activity was almost eliminated by 100μM SB203580, but significant JNK activity remained with 10μM SB203580 (**Fig. 4A**). However, 10μM SB203580 completely prevented inhibition of FAT by polyQ-Htt (**Fig. 4B**), suggesting that polyQ-Htt effects involved JNK2 or JNK3. Significantly, 10μM SB203580 also prevented inhibition of FAT by polyQ-AR<sup>7</sup>. JNK isoforms were distinguished using biochemical approaches. JSAP1 is a scaffold protein regulating JNK activation<sup>34</sup>. Four JSAP1 isoforms were identified (a,b,c and d), all containing a 17-amino acid JNK binding domain (JBD) homologous to the JIP peptide (**Fig. 4C**). A 31 amino acid insert in JSAP1c/JSAP1d selectively reduces binding to JNK<sup>34</sup>. As a result, JSAP1d binds JNK3 with lower affinity than JSAP1a, and inhibits JNK3 less efficiently<sup>34</sup>. Recombinant JSAP1a (amino acids 115–233) and JSAP1d (amino acids 115–264) polypeptides were expressed and purified, then co-perfused at 5μM with polyQ-Htt (**Fig. 4D**). Perfusion of JSAP1a and JSAP1d alone had no effect on FAT (not shown). As with JIP peptide (**Fig. 2E**), co-perfusion of polyQ-Htt and JSAP1a completely prevented inhibition of FAT by



polyQ-Htt (**Fig. 4D**). In contrast, JSAP1d reduced, but did not eliminate polyQ-Htt effects on FAT (**Fig. 4E**), suggesting JNK3 mediates polyQ-Htt effects in FAT.

Effects of specific JNK isoforms on FAT were evaluated in isolated axoplasm (**Fig. 5**). The activity of recombinant JNKs was normalized *in vitro* using c-Jun as substrate (data not shown). JNK1 (200nM) did not affect FAT (**Fig. 5A**), consistent with reports of constitutive JNK1 activity in neurons<sup>32,33</sup>. JNK2 (100nM) decreased anterograde FAT rates slightly (1.25  $\mu\text{m}/\text{sec}$ , compared to 1.6  $\mu\text{m}/\text{sec}$  for control buffer;  $P \leq 0.01$ , two-sample *t*-test) (**Fig. 5B**), but did not affect retrograde FAT (**Fig. 5D**). As with polyQ-Htt perfusion (**Fig. 5D**), JNK3 (100nM) inhibited both directions of FAT (**Fig. 5C**). Quantitative analysis showed that JNK3 inhibited both anterograde (0.9  $\mu\text{m}/\text{sec}$ ; compared to 1.6  $\mu\text{m}/\text{sec}$  in control buffer) and retrograde (1.25  $\mu\text{m}/\text{sec}$ , compared to 1.4  $\mu\text{m}/\text{sec}$  in control buffer) FAT at  $p \leq 0.01$ , two-sample *t*-test, suggesting that JNK3 is principally responsible for polyQ-Htt effects on FAT.

**JNK3 phosphorylates kinesin-1 at Ser176.** JNK3 phosphorylated kinesin-1, but not KLCs<sup>7</sup>. Using liquid chromatography tandem mass spectrometry (LC/MS/MS) we mapped residues in kinesin-1 phosphorylated by JNK3 (**Fig. 6** and **Supplemental Fig. 2**). Kinesin-1 constructs encompassing the first 584 amino acids of kinesin-1C (KHC<sup>584</sup>) were phosphorylated *in vitro* with JNK3 (**Fig. 6B**)<sup>7</sup> and compared to non-phosphorylated KHC<sup>584</sup>. Phosphorylated polypeptides were digested with trypsin directly for LC/MS/MS analysis or for phosphopeptide enrichment by IMAC<sup>35</sup> and LC/MS/MS analysis (**Supplemental Fig. 2**). Identification of mass spectrometry-generated peptides used the SEQUEST algorithm. KHC<sup>584</sup> identity was confirmed by identification of multiple kinesin-1C peptides (coverage of 72%) (**Supplemental Fig. 2**). Residual phosphorylation of several peptides was detected (not shown), but using analysis of protease cleavage sites, MS spectra, cross correlation (X-corr) as well as delta correlation (dCn) values, a unique peptide corresponding to amino acids 173-188, was identified with unequivocal evidence of phosphorylation by JNK3 (**Fig.**

**6A**, and **Supplemental Fig. 2**). Phosphatase treatment reduced the phosphorylated peak intensity compared to neighboring peaks (not shown). This JNK3-phosphorylated peptide was within the kinesin-1c motor domain and contained two serines (**Fig. 6A**). LC/MS/MS allowed precise mapping of the specific serine residue carrying the phosphorylation. Tandem mass spectrometry analysis by collision-induced dissociation (CID) indicated that phosphorylation occurs on Ser176, but not Ser175 (**Fig. 6** and **Supplemental Fig. 2**). Presence of a proline residue adjacent to Ser176 (a hallmark of JNK substrates) supported identification of Ser176 as the JNK3 phosphorylation site. Mass spectrometric analysis of JNK1-phosphorylated KHC<sup>584</sup> did not reveal phosphorylation at this site (**Supplemental Fig. 3**), consistent with differential effects of JNK1 and JNK3 on FAT (**Fig. 5A, C**). To confirm ESI-LC/MS/MS analysis, site-directed mutagenesis substituted alanine for either Ser175 or Ser176 of KHC<sup>584</sup> (KHC<sup>584</sup>-S175A and KHC<sup>584</sup>-S176A). Bacterially-expressed mutant proteins were purified (**Fig. 6B**), then phosphorylated *in vitro* with JNK3, and <sup>32</sup>P incorporation analyzed by Phosphorimaging. Phosphorylation of KHC<sup>584</sup>-S176A, but not KHC<sup>584</sup>-S175A, was reduced relative to wild-type KHC<sup>584</sup> by  $\approx 30\%$  (KHC<sup>584</sup>-WT, **Fig. 6B**). Ser176 is conserved among squid, mouse and human kinesin-1s (**Supplemental Fig. 4A**). Levels of <sup>32</sup>P incorporated in KHC<sup>584</sup>-S176A were consistent with mass spectrometry findings showing partial phosphorylation of KHC<sup>584</sup> *in vitro* at non-conserved residues outside the motor domain (not shown). Ser176 phosphorylation was also detected in kinesin-1 immunoprecipitated from mouse brain (not shown). Together, these data identified Ser176 as a major kinesin-1 residue phosphorylated by JNK3.

***Ser176 phosphorylation affects kinesin-1 function.*** Effects of polyQ-AR on FAT involved JNK activation, increased kinesin-1 phosphorylation and reduced microtubule binding of kinesin-1<sup>7</sup>. Ser176 localizes to loop 8, a sequence within the motor domain of kinesin-1 implicated in kinesin-1 interaction with microtubules (**Supplemental Fig. 4B**)<sup>36</sup>, suggesting its phosphorylation might

affect kinesin-1 binding to microtubules. NSC34 cells were transiently transfected with WT-Htt, or polyQ-Htt (see **Fig. 3A**). Total kinesin-1 levels were comparable for untransfected, WT-Htt, and polyQ-Htt-expressing cells (**Fig. 7A**). However, microtubule-binding assays using the non-hydrolysable ATP analog AMP-PNP<sup>7</sup> revealed a reduction in kinesin-1 binding to microtubules in polyQ-Htt-expressing cells relative to WT-Htt-expressing cells (**Fig. 7A**). Similar effects were observed when using immortalized striatal cell lines derived from wild type and Hdh<sup>Q109</sup> mice (not shown). This was consistent with reduced kinesin-1 binding to microtubules in cells expressing polyQ-AR<sup>7</sup>.

Recombinant KHC<sup>584</sup> was incubated with 100 $\mu$ M radiolabeled <sup>32</sup>P- $\gamma$ ATP in the presence or absence of active JNK3 (**Fig. 7B**), then incubated with purified microtubules in the presence of AMP-PNP (2 mM) or 2 mM ATP (to control for non-specific pelleting, not shown). Microtubule pellets (P) and corresponding supernatants (SN) were analyzed by immunoblot to visualize non-phosphorylated KHC<sup>584</sup> and autoradiography to visualize JNK3-phosphorylated KHC<sup>584</sup>. In the presence of AMP-PNP, kinesin-1 forms a rigor structure with microtubules<sup>13</sup>. Virtually all non-phosphorylated KHC<sup>584</sup> partitioned with microtubules by immunoblot (**Fig. 7B**), but a large fraction of JNK3-phosphorylated KHC<sup>584</sup> remained in the SN (**Fig. 7B**), suggesting that phosphorylation of kinesin-1 by JNK3 inhibits kinesin-1 binding to microtubules. The presence of JNK3-phosphorylated KHC<sup>584</sup> in P fractions was consistent with residual phosphorylation at residues outside the motor domain. JNK-3 phosphorylation of kinesin-1 reduced binding to microtubules with AMP-PNP by  $\approx$ 50% (**Supplemental Fig. 5**).

Effects of S176 phosphorylation on kinesin-1 motility *in vivo* were assessed by expressing GFP-tagged, truncated kinesin-1 constructs in cultured hippocampal neurons (**Fig. 8**). When expressed in hippocampal cells, a GFP-tagged kinesin-1 construct (KHC<sup>560</sup>-GFP -WT) selectively translocates to axon distal ends and accumulates, but not in dendrites, indicating that this motor translocates

preferentially along axonal microtubules<sup>37</sup>. KHC<sup>560</sup>-GFP-WT translocation is so efficient that little or no fluorescence can be detected within cell bodies or along axons<sup>37</sup>. To evaluate whether S176 phosphorylation affects kinesin translocation efficiency, we compared localization of phosphorylation-mimicking construct KHC<sup>560</sup>-GFP-S176E and its unphosphorylatable counterpart KHC<sup>560</sup>-GFP-S176A to that of KHC<sup>560</sup>-GFP-WT by quantitative fluorescence microscopy (**Fig. 8A–F**). Much less phosphomimetic KHC<sup>560</sup>-GFP-S176E construct accumulated at axonal tips than the KHC<sup>560</sup>-GFP-WT construct ( $56 \pm 2\%$  vs.  $87 \pm 3\%$ , respectively, mean  $\pm$  SEM; T-test,  $p < 0.0001$ ) (**Fig. 8G**), with more KHC<sup>560</sup>-GFP-S176E fluorescence in cell bodies and faint staining of neurites (**Fig. 8C**), the expected pattern if a significant fraction of phosphomimetic kinesin-1 were distributed like a soluble protein. Slightly less KHC<sup>560</sup>-GFP-S176A accumulated at axon tips ( $79\% \pm 2\%$ ) compared to KHC<sup>560</sup>-GFP-WT, but accumulations were still significantly higher than KHC<sup>560</sup>-GFP-S176E (t-test,  $p < 0.0001$ ) (**Fig. 8G**). Thus, a mutation of Ser176 mimicking phosphorylation reduces efficiency of processive kinesin-1 translocation in cultured neurons.

## **DISCUSSION**

Despite ubiquitous expression of Htt, neuronal cells are uniquely vulnerable to the toxic gain-of-function in polyQ-expansion, suggesting that processes critical for proper neuronal function and survival are selectively altered in HD<sup>3</sup>. Axonal transport is essential for neurons, due to their large size and complex functional architecture<sup>3</sup>. Significantly, alterations in kinesin-1 function and regulation are associated with various human neuropathologies<sup>3, 7, 38-40</sup>.

Several reports link FAT inhibition to pathogenesis in HD<sup>4, 5, 8, 10</sup> and other polyQ-expansion diseases<sup>3, 7</sup>. For example, overexpression of polyQ-Htt in cultured cells<sup>10</sup> and *Drosophila*<sup>4, 5</sup> leads to reduced transport and accumulation of vesicular cargos within axons. PolyQ-Htt and polyQ-AR, two otherwise unrelated proteins, similarly inhibit FAT vesicle motility in isolated axoplasm

independently of changes in gene transcription or aggregate formation<sup>7,8</sup>. Such observations implicate FAT defects in HD pathogenesis, which would partially explain the selective vulnerability of neurons in HD and other polyQ-expanded diseases<sup>3</sup>.

Several models were proposed to explain the inhibition of FAT induced by polyQ-Htt. Some require physical interactions between Htt and conventional kinesin<sup>41</sup> or CDyn subunits<sup>9,10,12</sup>. PolyQ-Htt aggregates were proposed to sequester molecular motors<sup>4,6</sup>, or physically block FAT<sup>5,42</sup>.

Alternatively, Htt mutations were suggested to interfere with normal functions of Htt as a scaffold linking molecular motors to transported cargoes<sup>9,10,11</sup>, or to affect the subunit composition and function of molecular motors<sup>12</sup>. However, axoplasm experiments indicated that polyQ-Htt inhibited FAT at concentrations 100-1000 fold lower than molecular motors, suggesting activation of enzymatic activities<sup>3,7,8</sup>.

Cell fractionation and immunoprecipitation evaluated interactions between Htt and molecular motors in brain tissue from wild-type and homozygous Hdh<sup>Q109</sup> mice. Regardless of genotype, similar levels of full-length Htt were found in detergent-soluble (S) and detergent-insoluble (I) fractions. In contrast, KHCs, KLCs, DIC and DHC levels were much higher in soluble fractions, suggesting that most molecular motors are not sequestered by polyQ-Htt. Unlike experiments involving Htt overexpression, immunoprecipitation failed to detect interactions between endogenous Htt and kinesin<sup>41</sup> or CDyn<sup>12</sup> (**Fig. 1**). Detection of KLCs in KHC- and DHC in DIC-immunoprecipitates confirmed that physiologically relevant protein complexes were preserved<sup>13,14</sup>. Such observations are inconsistent with models in which polyQ-Htt inhibits FAT through direct interactions with molecular motors.

Another model proposed that pathogenic polyQ-Htt activates neuronal regulatory pathways that affect FAT<sup>3</sup>. Kinesin-1 and CDyn are regulated by phosphorylation of specific motor subunits<sup>7,18</sup>. Kinase activities that regulate FAT, including GSK-3<sup>43</sup>, Akt<sup>44</sup>, and JNK<sup>20,22,45</sup> are altered in

Huntington's and polyQ-AR activates JNK<sup>7</sup>. JNK inhibitors blocked polyQ-Htt effects on FAT and JNK activation was documented in polyQ-Htt-expressing cells and Hdh<sup>Q109</sup> mice (**Fig. 3**). JNK activation was more pronounced in homozygous Hdh<sup>Q109</sup> mice than heterozygous littermates, but increased in both, consistent with autosomal dominant inheritance of HD. JNK activation in presymptomatic Hdh<sup>Q109</sup> mice indicated that this change represents an early event in HD.

Mammals have three JNK genes (JNK1, JNK2 and JNK3)<sup>46</sup>. Analysis of JNK in Hdh<sup>Q109</sup> mice and polyQ-Htt-transfected cells indicated that polyQ-Htt increased JNK2/3 activity more than JNK1 (**Fig. 3**), consistent with reports showing constitutive JNK1 activity and selective JNK2/3 activation in neurons with stress<sup>32,33</sup>. This prompted us to examine roles for specific JNK isoforms mediating polyQ-Htt effects on FAT. SB203580 inhibits JNK2/3 at 10 $\mu$ M, but JNK1 inhibition requires  $\geq 100\mu$ M<sup>23</sup>. Significant JNK activity (presumably JNK1) remains in axoplasms treated with 10 $\mu$ M SB203580 (**Fig. 4A**), but 10 $\mu$ M SB203580 prevented polyQ-Htt effects on FAT (**Fig. 4B**), suggesting that polyQ-Htt effects on FAT involve JNK2/3. JSAP1 polypeptides further supported a role for JNK3, because JSAP1a, which inhibits all JNKs, preserved FAT effectively, but JSAP1d, with a 31- amino acid insert that selectively interferes with JNK3 binding<sup>34</sup> did not (**Fig. 4D–E**). To evaluate the role of individual JNKs on FAT, effects of active recombinant JNK1, JNK2 and JNK3 on FAT were evaluated in axoplasm. Active JNK1 had no effect on FAT (**Fig. 5A**), consistent with constitutive JNK1 activity in axons<sup>32,33</sup> (**Fig. 4A**). JNK2 produced a selective, moderate effect on anterograde FAT, but no effect on retrograde FAT. In contrast, JNK3 effects on FAT paralleled those of polyQ-Htt by inhibiting both anterograde and retrograde FAT. Although JNK2 may contribute, JNK3 appears to primarily mediate polyQ-Htt effects on FAT. Notably, JNK3 is preferentially expressed in nervous tissues<sup>47</sup> and polyQ-Htt pathology is restricted to neurons.

To provide a molecular basis for FAT inhibition by JNK3, relevant phosphorylation sites were

identified. Mass spectrometry mapped JNK3 phosphorylation of kinesin-1 to S176, a conserved residue in the motor domain (**Fig. 6A**, **Supplemental Fig. 2–3**). S176 was also modified in kinesin-1 immunoprecipitated from mouse brain (not shown). Mutagenesis studies confirmed that JNK3 phosphorylated Ser176 (**Fig. 6B**). JNK1 did not phosphorylate kinesin-1 at Ser176 (**Supplemental Fig. 3**), consistent with unique substrate preferences for JNK3<sup>48</sup>. Ser176 was conserved among squid, mouse and human kinesin-1s (**Supplemental Fig. 4A**), validating the squid axoplasm model. Collectively, these data demonstrate that JNK3 activity is elevated in brains of Hdh<sup>Q109</sup> mice and axoplasm perfused with polyQ-Htt (**Fig. 3–4**); that JNK3 phosphorylates kinesin-1 at Ser176 (**Fig. 6** and **Supplemental Fig. 2–3**), and that Ser176 modification is sufficient to inhibit trafficking of kinesin-1 (**Fig. 8**). Antibodies selective for this epitope are under development and should allow us to quantify the fraction of neuronal kinesin-1 modified by JNK3 in HD brains.

Based on the Ser176 position within the motor domain<sup>36</sup>, we evaluated effects of JNK3 phosphorylation on kinesin-1 binding to microtubules. JNK3-treated recombinant kinesin-1 and kinesin-1 in polyQ-Htt-transfected cells exhibited reduced binding to microtubules (**Fig. 7**). Further, pseudophosphorylation at Ser176 dramatically decreased kinesin-1 translocation *in vivo* (**Fig. 8**), indicating that Ser176 phosphorylation interferes with kinesin-1 function.

Our results suggest that polyQ-Htt inhibits FAT by activation of axonal JNKs. Additionally, JNK activation by polyQ-Htt is also consistent with changes in transcription<sup>49</sup>, and JNKs can be pro-apoptotic<sup>30</sup> (**Supplemental Fig. 6**). Significantly, JNK3, and not JNK1, activity mediated polyQ-Htt effects on FAT, providing a partial explanation for selective neuronal vulnerability in HD. JNK1 and JNK2 are ubiquitously expressed, whereas JNK3 is selectively expressed in brain and testes<sup>47</sup>. Identification of kinesin-1 as a novel JNK3 substrate provided a molecular basis for changes in FAT consistent with neuron-selective pathology of polyQ-Htt.

In sum, neuronal JNK3 is activated by polyQ-Htt. JNK3 in turn phosphorylates kinesin-1, decreasing its ability to bind microtubules and move cargoes in FAT (**Fig. 8** and **Supplemental Fig. 6**). Identification of Ser176-phosphorylated kinesin-1 in normal mouse brain suggests a role of JNK3 in a normal pathway for regulating kinesin and delivering specific MBO cargoes to particular neuronal domains. Increased activation of this pathway by polyQ-Htt would lead to reductions in kinesin-based transport, deficits in synaptic and axonal function, and eventual dying-back neuronal degeneration<sup>3</sup>. Inhibition of JNK3 sufficed to prevent inhibition of FAT due to polyQ-Htt. These results suggest that elevation of JNK activity and consequent inhibition of FAT may represent primary pathogenic events in Huntington's disease. Further studies should illuminate molecular components mediating JNK activation by polyQ-Htt. Regardless; inhibition of JNK activity to protect FAT represents a promising therapeutic target for treatment of Huntington's disease.

**Author Contributions:** GAM and STB performed transport and biochemistry experiments and wrote the manuscript; YY, SLP, AK, KL performed transport and biochemistry experiments; KY provided and characterized recombinant JIP; BB, ETC, CB and DH performed Mass Spectrometry studies; and CFH and GB did GFP-kinesin experiments. All authors reviewed and edited the manuscript



## **FIGURE LEGENDS**

**Figure 1: Endogenous Htt does not interact with molecular motors.** **A)** Detergent-soluble brain lysates obtained from wild type (WT) and 14 month-old Hdh<sup>Q109</sup> knock-in (polyQ) mice were immunoprecipitated with antibodies against Htt, kinesin-1 (KHC), or dynein intermediate chains (DIC). Immunoblots of resulting immunoprecipitates (IPP) showed that anti-kinesin-1 antibodies (H2<sup>13</sup>) effectively precipitated both kinesin-1 heavy (KHC) and light chains (KLC), but failed to precipitate Htt, dynein heavy chain (DHC) or dynein intermediate chain (DIC). Similarly, anti-DIC antibodies (74.1<sup>16</sup>) immunoprecipitated DIC and DHC, but not Htt. Conversely, anti-Htt antibodies effectively immunoprecipitated Htt, but not KHC, KLC, DIC or DHC. Immunoprecipitation with non-immune mouse IgG (NMIgG) provided a control for non-specific immunoprecipitation. An aliquot of each brain lysate before immunoprecipitation (Input) was used as a positive control. **B)** Detergent-soluble brain lysates from wild type (WT-Htt) and Hdh<sup>Q109</sup> knock-in (polyQ-Htt) mice were subjected to three cycles of immunoprecipitation with antibodies against kinesin-1. Aliquots of each supernatant (SN1-3) were analyzed by immunoblot. Note reductions in both KHC and KLC immunoreactivity with each cycle. In contrast, no change in Htt levels was detected, regardless of mouse genotype. Immunoprecipitations with a non-immune mouse IgG (Ctrl) served as a control for non-specific precipitation of proteins.

**Figure 2: JNK inhibitors prevent polyQ-Htt-induced FAT inhibition.** Vesicle motility assays in isolated axoplasm show individual velocity measurements (arrowheads) as a function of time. Dark arrowheads and line show anterograde kinesin-dependent FAT rates and reverse grey arrowheads and line show retrograde, cytoplasmic dynein-dependent FAT rates. *In vitro* translated Htt constructs were perfused as before<sup>8</sup>. **A)** Perfusion of WT-Htt does not affect FAT<sup>8</sup> **B)** Perfusion of polyQ-Htt inhibited both anterograde and retrograde FAT<sup>8</sup>. **C)** Endogenous JNK activity in squid

axoplasm is revealed by *in vitro* phosphorylation assays. A time-dependent increase in cJun phosphorylation at JNK sites (cJun S63/73) is seen when GST-cJun is incubated with squid axoplasm lysates (Axo). Phosphorylation of GST-cJun is completely inhibited by either SP600125 or JIP peptide (JIP), two well-characterized JNK inhibitors. Anti-GST antibody shows similar GST-cJun levels for each reaction (cJun Total). Co-perfusion of polyQ-Htt with either **D**) SP600125 (500nM) or **E**) JIP peptide (100  $\mu$ M) completely prevented inhibition of FAT elicited by polyQ-Htt (compare D-E with B). **E**) In contrast, co-perfusion of polyQ-Htt with the histone deacetylase inhibitor BC-6-25<sup>27</sup> (10 $\mu$ M) failed to prevent polyQ-Htt effects on FAT. These results indicate that polyQ-Htt-mediated inhibition of FAT involves activation of endogenous axoplasmic JNK.

**Figure 3: PolyQ-Htt increases JNK activity in Huntington's disease models.** JNK activation was evaluated by immunoblots with active JNK (pJNK) and total JNK (pan-JNK) antibodies, which mainly recognized bands at p54 and p46. **A**) NSC34 cells transfected with WT-Htt (18Q) or polyQ-Htt (56Q) constructs were analyzed after 24h. Both endogenous (End) and exogenous (Exo) Htt were detectable. Total JNK (Pan-JNK) was similar for untransfected (Ctrl), WT-Htt (WT) and polyQ-Htt (polyQ) transfected cells, but phosphorylated p54 JNK (pJNK) increased with polyQ-Htt. **B**) JNK1, JNK2 and JNK3 antibody specificity were validated with GST-JNKs (left), and striatal lysates with individual JNK genes ablated (right). JNK1, JNK2 and JNK3 antibodies showed no immunoreactivity in brains from corresponding knockout samples. **C**) Striata from wild type (WT), heterozygous (Hetero) and homozygous (Homo) Hdh<sup>Q109</sup> mice showed similar Total JNK (pan-JNK) regardless of genotype, whereas active JNK (pJNK) increased in Hdh<sup>Q109</sup> mice. Akt activation (p-Akt) was similar for all mice. **D**) Immunoblots using NSC34 (top) and mouse brain **striatum** (bottom) showed JNK1 co-migrating with p46, whereas JNK2 and JNK3 co-migrated with p54. **E**) Quantitative analysis of immunoblots in C showed activation of both p54 and p46 JNK in Hdh<sup>Q109</sup>

mice. pJNK/JNK ratios for JNK1 (p46) or JNK2/3 (p54) indicated that both JNK2/3 and JNK1 activity were higher in homozygous than heterozygous *Hdh<sup>Q109</sup>* mice. JNK2/3 was activated to a greater extent than JNK1, suggesting differential activation of JNKs by polyQ-Htt. Differences between JNK2/3 activity in WT and *Hdh<sup>Q109</sup>* were significant ( $p \leq 0.01$  in a pooled t-test).

**Figure 4. The effects of polyQ-Htt on FAT are mediated by JNK3.** SB203580 blocks the action of pathogenic androgen receptor on FAT<sup>8</sup>, but SB203580 is a poor inhibitor of JNK1 ( $IC_{50} \geq 100 \mu M$ ) and a good inhibitor of JNK2/3 ( $IC_{50} \approx 10 \mu M$ )<sup>23</sup>. **A)** *In vitro* phosphorylation assays in axoplasm showed a dose-dependent inhibition of axoplasmic JNK activity by SB203580. Notably, significant JNK activity remained in the presence of  $10 \mu M$  SB203580, presumably representing endogenous JNK1 activity. **B)** In contrast, vesicle motility assays in isolated squid axoplasm show that effects of polyQ-Htt on FAT were blocked by SB203580 at  $10 \mu M$ , which is consistent with an action on JNK2/3. **C)** Sequence alignment of a JIP peptide inhibitor (Calbiochem) with portions of JSAP1a and JSAP1d polypeptides<sup>34</sup>. The boxed region indicates the highly conserved JNK binding domain (JBD). A 31-aminoacid peptide sequence unique to JSAP1d (underlined) selectively interferes with binding to JNK3<sup>34</sup>. **D)** Co-perfusion of polyQ-Htt with JSAP1a ( $5 \mu M$ ) which blocks both JNK1 and JNK3 activity, effectively prevents effects of polyQ-Htt on FAT. **E)** Co-perfusion of polyQ-Htt with JSAP1d ( $5 \mu M$ ), which preferentially inhibits JNK1, only partially blocks polyQ-Htt effects. These results suggest that JNK3 mediates the effects of polyQ-Htt on FAT.

**Figure 5. Active JNK3 mimics the effect of polyQ-Htt on FAT.** Effects of active, recombinant JNK1, JNK2 and JNK3 were evaluated by vesicle motility assays in isolated axoplasm. **A)** Perfusion of active JNK1 kinase (200nM) in axoplasm had no effect on FAT. **B)** Perfusion of active JNK2 (100nM) slightly inhibited anterograde FAT, but had no significant effect on retrograde FAT.

C) Perfusion of JNK3 (100nM) significantly inhibited FAT in both directions, as observed with polyQ-Htt (compare to **Fig. 2B**) D) Bar graphs showing mean FAT rates in axoplasm perfused with active JNKs and polyQ-Htt. Error bars show SEM. Data represent pooled FAT rate measurements between 30-50 min of observation. Anterograde FAT rates after polyQ-Htt perfusion were comparable to those elicited by perfusion of active JNK3 and both JNK3 and polyQ-Htt significantly inhibit retrograde FAT.

**Figure 6. JNK3 phosphorylates kinesin-1 heavy chains at Ser176. A)** Mass spectrometry studies identified a tryptic peptide within the motor domain of kinesin-1 (amino acids 173-188) showing unequivocal evidence of phosphorylation by JNK3 (see also **Supplemental Fig. 2**). **B)** Recombinant KHC<sup>584</sup>-WT protein was incubated in the presence (+) or absence (-) of active JNK3 and <sup>32</sup>P-ATP, and analyzed by SDS-PAGE. The ability of JNK3 to phosphorylate KHC<sup>584</sup> at S175 and S176 was also evaluated using KHC<sup>584</sup>-S175 and KHC<sup>584</sup>-S176A mutants. An autoradiogram (<sup>32</sup>P) showed a dramatic reduction in the phosphorylation of a KHC<sup>584</sup>-S176A (S176A) construct relative to wild type (WT) and KHC<sup>584</sup>-S175A (S175A) constructs (arrow). Coomassie blue (CB) staining showed comparable amounts of KHC<sup>584</sup> in all lanes. Asterisk indicates autophosphorylated JNK3. These results indicated that S176 is the main residue phosphorylated by JNK3.

**Figure 7. PolyQ-Htt expression inhibits kinesin-1 binding to microtubules. A)** Lysates of NSC34 cells transfected with WT-Htt or polyQ-Htt as in **Fig. 3A** were analyzed by immunoblot. Total levels (Input) of kinesin-1 (KHC), dynein heavy chain (DHC) and tubulin (Tub) were comparable for untransfected (Ctrl), WT-Htt and polyQ-Htt-expressing cells. However, the fraction of kinesin-1 recovered in association with microtubules was reduced for lysates from polyQ-Htt expressing cells, when compared to untransfected and WT-Htt-expressing cells. **B)** Microtubule-

binding assays using recombinant kinesin-1 (KHC<sup>584</sup>). Immunoblot (WB) shows that unphosphorylated KHC<sup>584</sup> is mainly recovered in association with microtubules (Pellet). An autoradiogram (<sup>32</sup>P) reveals a significant fraction of JNK3-phosphorylated KHC<sup>584</sup> remains in the supernatant.

**Figure 8. A mutation mimicking Ser176 phosphorylation reduces the translocation efficiency of constitutively active kinesin-1 in cultured hippocampal neurons.** **A-F:** Representative stage 3 neurons were co-transfected with GFP-tagged constructs encompassing the first 560 amino acids of kinesin-1 (KHC<sup>560</sup>, **A**, **C**, and **E**) and mCherry, a soluble marker protein that diffuses throughout the cell (**B**, **D**, and **F**, scale bar= 20 $\mu$ m). Cells were fixed with formaldehyde and imaged 5 hours after transfection. Wild type (WT, **A**) and non-phosphorylatable S176A mutant (S176A, **E**) constructs efficiently translocated so that they were localized almost exclusively at the axon tip. In contrast, a significant fraction of the pseudophosphorylated S176 mutant (S176E, **C**) was found throughout the cell body. Arrowheads in **A**, **C** and **E** indicate the location of the neuronal cell bodies as seen in **B**, **D**, and **F**. **G:** The percentage of total KHC<sup>560</sup>-GFP fluorescence localized at the axon tip was measured in cells expressing KHC<sup>560</sup> WT (N=22), KHC<sup>560</sup> S176E (N=33) or KHC<sup>560</sup> S176A (N=30). Significantly less KHC<sup>560</sup> S176E accumulated at axon tips with the wild-type construct (t-test,  $p<0.0001$ ); only marginally less KHC<sup>560</sup> S176A accumulated at the axon tip than the wild-type construct (t-test,  $p\sim 0.05$ ). Bars show mean and standard deviation.

## **SUPPLEMENTAL FIGURES**

**Supplemental Figure 1. PolyQ-Htt does not affect motor protein solubility.** **A)** Brain lysates from wild type and Hdh<sup>Q109</sup> knock-in mice expressing endogenous levels of normal (WT-Htt) or pathogenic Htt (polyQ-Htt) were fractionated into detergent (TX-100) soluble and insoluble fractions. The distribution of major subunits of conventional kinesin and cytoplasmic dynein subunits were analyzed by immunoblot: Kin: (kinesin-1, kinesin heavy chain), DHC (dynein heavy chain); DIC: (dynein intermediate chain), Note that while Huntingtin (Htt) protein partitions similarly in both fractions, the bulk of molecular motors was recovered in the supernatant fraction. There was no evidence of increased motor protein insolubility induced by polyQ-Htt expression. **B)** Detergent-soluble brain lysates from wild type (WT-Htt) and Hdh<sup>Q109</sup> knock-in (polyQ-Htt) mice were subjected to three cycles of immunoprecipitation with antibodies against DIC, as in **Fig. 1B**. Aliquots of input material (Input) or the supernatant after three immunoprecipitation cycles (SN3) were analyzed by immunoblot with antibodies against DIC and Htt. Note the marked depletion of DIC immunoreactivity after immunoprecipitation with DIC-specific antibodies. Immunoprecipitates with a non-immune IgG (Ctrl) served as a control for non-specific precipitation of proteins in these experiments. In contrast, no change in Htt levels was detected, regardless of mouse genotype.

**Supplemental Figure 2. Mass spectrometry analysis of kinesin-1.** **A)** Diagram of mass spectrometry protocols for analysis of kinesin-1 phosphorylation by JNK3 and JNK1. **B)** The amino acid sequence of the KHC<sup>584</sup> construct is shown. Residues in red indicate amino acid coverage (72%). The sequence corresponding to the motor domain of kinesin-1c (KIF5C) is outlined. The major phosphopeptide identified in these studies (amino acids 173-188) is marked in bold. **C)** Relevant details of the 173-188 phosphopeptide identification are shown including its sequence (e), charge (a), mass (b), cross correlation (c), and delta correlation (d) values (top). Mass spectrum of

the 173-188 phosphopeptide. The graph plots ion intensity vs. mass (M) ion charge (Z) ratio for  $b+$  (red) and  $y+$  (blue) ions. The peptide sequence (top) shows a detail of the identified residues.

**Supplemental Figure 3. KHC<sup>584</sup> motor domain is phosphorylated by JNK3, but not by JNK1.**

KHC<sup>584</sup> was phosphorylated *in vitro* using either JNK3 or JNK1 (as shown in **Figure 7B**), and samples processed for mass spectrometry analysis as described in Material and Methods. Full spectra (Full ms) corresponding to the retention time of the 173-188 phosphopeptide (RT: 58.44 minutes) are shown. The red arrow points the peak corresponding to the precursor ion of the phosphopeptide (m/z of 930.4). Note that this peak is present only in Full ms of JNK3-phosphorylated KHC<sup>584</sup> samples (left), but not in Full ms of JNK1-phosphorylated KHC<sup>584</sup> samples (right). The black arrow and dashed red line point the area of the Full ms where the peak for the precursor ion should be found. The activities of recombinant JNK1 and JNK3 were normalized using c-Jun as a substrate. These results indicate that JNK3, but not JNK1, can phosphorylate the Ser176 residue in kinesin-1.

**Supplemental Figure 4. Ser176 is a conserved residue in the Kinesin-1 microtubule-binding domain.**

**A)** Sequence alignment shows that Ser176 (boxed) is conserved among human, mouse and squid sequences for kinesin-1. **B)** Ser176 is located in a surface loop of KHC motor domain, a region implicated in binding of kinesin-1 to microtubules<sup>36</sup>.

**Supplemental Figure 5. JNK3 phosphorylation of KHC<sup>584</sup> reduces binding to microtubules.**

The histogram shows quantitation of immunoblots and autoradiograms in Figure 7B. The ratio of KHC<sup>584</sup> in microtubule pellets and supernatants (P/S) reveals a dramatic reduction in KHC binding to microtubules upon phosphorylation by JNK3.

**Supplemental Figure 6. Inhibition of conventional kinesin-based motility induced by pathogenic Htt (polyQ-Htt).** Our results showing increased activation and phosphorylation of JNKs induced by polyQ-Htt suggest that this mutant polypeptide activates specific MAPKKs and MAPKKs (dashed arrow) upstream of JNK. Increased JNK1 activation is linked to alterations in the activity of various transcription factors (i.e., ATF-2 and c-Jun, among others), consistent with widely reported changes in gene transcription in Huntington's disease<sup>49</sup>. Activation of JNK3 on the other hand, would lead to phosphorylation of kinesin-1 and likely other axonal substrates (question mark). Data in this work indicates that phosphorylation of kinesin-1s by JNK3 results in reduced binding of conventional kinesin to microtubules. Reductions in the delivery of critical axonal cargoes by conventional kinesin would result in impaired synaptic function and dying-back degeneration of neurons<sup>3</sup>.

**Supplemental Figure 7: Characterization of antibodies used in this study.** **A)** Immunoblot analysis of whole mouse brain lysates using antibodies against molecular motors. From left to right: HTT: anti-huntingtin (2166, Chemicon); DHC), anti-dynein heavy chain (Santa Cruz #9115); DIC: anti-dynein intermediate chain (clone 74.1, Santa Cruz #13524); H2: anti-kinesin heavy chain (H2 clone, Chemicon)<sup>13</sup>; 63-90: anti-pan KLCs (63-90 clone, Chemicon)<sup>13</sup>. **B)** Immunoblot analysis of mouse striatum lysates using antibodies against JNKs. Pan-JNK: anti-pan-JNK (Upstate #06-748); pJNK: anti-phospho JNK (Cell Signaling #9251); JNK1: anti-JNK1 (PharMingen #554268); JNK2: anti-JNK2 (Cell Signaling #4672); JNK3: anti-JNK3 (Cell Signaling #2305). **C)** Immunoblot analysis of NSC34 lysates using antibodies against JNKs. Antibodies are the same as in **B**. Molecular weight markers (Invitrogen#LC5925) are indicated at the left side of each panel. See Material and methods for a detailed description of SDS-PAGE conditions.



## **MATERIAL AND METHODS**

***Antibodies and Reagents:*** The following antibodies were used: anti-KHC (H2 clone, Chemicon)<sup>13</sup>, anti-pan KLCs (63-90 clone, Chemicon)<sup>13</sup>, anti-dynein intermediate chain (Santa Cruz #13524), anti-dynein heavy chain (Santa Cruz #9115), anti-phospho Akt (44-622G, Biosource), anti-Htt (2166, Chemicon), anti-pan-JNK (Upstate #06-748), anti-JNK1 (Pharmingen #554268), anti-JNK2 (Cell Signaling #4672), anti-JNK3 (Cell Signaling #2305), anti-phospho JNK (Cell Signaling #9251), anti-GST (Sigma #G7781), anti-phospho c-Jun (Santa Cruz #16312), anti-tubulin (DM1A, Sigma). All antibodies were characterized for specificity against the tissues used (see **Supplemental Figure 7**). The following secondary antibodies were used: Jackson 111-035-045 HRP-conjugated goat anti-rabbit, Jackson 115-035-146 HRP-conjugated goat anti-mouse IgG, and Jackson 805-035-180 HRP-conjugated bovine anti-goat IgG.

SB203580, SP600125 (JNK inhibitor II), okadaic acid, staurosporine, K252a, 50nM okadaic acid, microcystin and c-Jun were obtained from Calbiochem. The HDAC inhibitor BC-6-25<sup>27</sup> was a generous gift from Alan Kozikowski (UIC). Inhibitor stocks were prepared in DMSO. Active JNK kinases were from Upstate (JNK1 #14-327, JNK2 #14-329, and JNK3 #14-501). His-tagged KHC<sup>584</sup> protein constructs were expressed in BL21-Codon Plus (DE3) *E. coli* (Stratagene), and purified using Talon beads (Clontech). Trx-tagged JSAP1 polypeptides were expressed and purified as described before<sup>34</sup>.

***Immunoblots:*** Proteins were separated by SDS-PAGE on 4-12% Bis-Tris gels (NuPage minigels, Invitrogen), using MOPS Running Buffer (Invitrogen) and transferred to PVDF using Towbin buffer supplemented with 10% (v/v) methanol (90 minutes at 400mA using Hoeffer TE22 apparatus). Immunoblots were blocked with 1% (w/v) non-fat dried milk in TBS (25 mM Tris pH 7.2, 2.68 mM KCl, 136.8 mM NaCl). Membranes were incubated with primary antibodies overnight at 4° C in 1% IgG free-BSA (Jackson ImmunoResearch), and washed four times with 0.1% Tween-

20 in TBS. Primary antibody binding was detected with HRP-conjugated anti-mouse, anti-rabbit or anti-goat antibodies (Jackson ImmunoResearch), and visualized by chemiluminescence (ECL, Amersham). Quantitative immunoblotting was performed as before<sup>39</sup>.

**Immunoprecipitation:** Mouse brains from wild-type and *Hdh<sup>Q109</sup>* knock-in mice were homogenized in lysis buffer (LB; 25 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, and mammalian protease inhibitor cocktail (Sigma, 1/100 dilution)]. Lysates were centrifuged twice for 5 minutes at 55,000 rpm (163,640  $g_{\max}$ ) using a TLA 100.3 rotor (Beckman Instruments, Palo Alto, CA). The resulting supernatant fractions were precleared using a mixture of Protein G agarose beads (Pierce), and non-immune mouse IgG-conjugated Sepharose beads (Jackson ImmunoResearch) for 1 hour at RT. 400  $\mu$ g of each precleared brain lysate were brought to 1 ml with LB, and incubated with 5  $\mu$ g of the appropriate antibody plus 10  $\mu$ l of Protein G agarose beads at 4<sup>o</sup> C for 3hs. Immunocomplexes were recovered by centrifugation (3000  $g_{\max}$  for 30 seconds), washed four times with 1 ml LB, once with 50mM HEPES pH 7.4, and resuspended in Laemmli buffer. For immunodepletion experiments (**Fig. 1B and supplemental Fig. 1B**), precleared mouse brain lysates were subject to three cycles of immunoprecipitation with H2 or DIC antibodies as above. After each immunoprecipitation cycle, a 50  $\mu$ l aliquot of each supernatant was saved for immunoblot analysis, as before<sup>13,14</sup>.

**Vesicle Motility assays in isolated axoplasm:** Axoplasm was extruded from giant axons of the squid *Loligo pealii* (Marine Biological Laboratory) as described previously<sup>7,8</sup>. Recombinant proteins, peptides or inhibitors were diluted into X/2 buffer (175 mM potassium aspartate, 65 mM taurine, 35 mM betaine, 25 mM glycine, 10 mM HEPES, 6.5 mM MgCl<sub>2</sub>, 5 mM EGTA, 1.5 mM CaCl<sub>2</sub>, 0.5 mM glucose, pH 7.2) supplemented with 2-5 mM ATP and 20  $\mu$ l added to perfusion chambers. Preparations were analyzed on a Zeiss Axiomat with a 100X, 1.3 n.a. objective, and DIC optics. Hamamatsu Argus 20 and Model 2400 CCD camera were used for image processing and

analysis. Organelle velocities were measured with a Photonics Microscopy C2117 video manipulator (Hamamatsu).

**Recombinant Constructs:** Expression vectors encoding amino acids 1–548 of human Htt with an N-terminal FLAG epitope tag were translated *in vitro* as described previously<sup>8</sup>, and used for vesicle motility assays. Expression vectors encoding amino acids 1-969 of human Htt (wild type (Q16) and pathogenic (Q46)) with an N-terminal FLAG tag were used for transfection studies (**Fig. 3A** and **7A**)<sup>29</sup>. His-tagged KHC<sup>584</sup>-S176A, KHC<sup>584</sup>-S176A, and GFP-tagged KHC<sup>560</sup> mutant constructs were generated using the Quick-site mutagenesis kit (Stratagene).

**Axoplasmic JNK activity assays:** For experiments on kinase activity in axoplasm (**Figs. 2C** and **4A**), 3- 4 axoplasms were triturated in 280μl of KB buffer (KB: 10mM Hepes pH 7.4, 10mM MgCl<sub>2</sub>, 1mM DTT) minus ATP. Reactions (50μl) were incubated at RT and started by adding ATP (50μM). Aliquots were collected at various time points up to 20 minutes and analyzed by immunoblotting.

**Brain Tissue/Cell lysate preparation:** Mouse brain tissue and cultured cells were homogenized in ROLB buffer [10mM Hepes pH7.4, 0.5% Triton X-100, 80mM β-glycerophosphate, 50mM Sodium Fluoride, 2mM Sodium Orthovanadate, 100nM Staurosporine, 100nM K252a, 50nM Okadaic acid, 50nM Microcystin, 100mM Potassium Phosphate and mammalian protease inhibitor cocktail (Sigma)]. Lysates were clarified by centrifugation, and protein concentration determined using BCA kit (Pierce). All mouse use was under protocols approved by the Institutional Animal Care and Use Committee at UIC and followed NIH guidelines for vertebrate animal use.

**NSC34 Cell Culture and Transfection:** NSC34 cells were plated at 10,000 cells/cm<sup>2</sup> on 10 cm tissue culture dishes for biochemical studies and grown on DMEM containing 1mM glutamine and 10% Fetal Bovine Serum (Hyclone). When cells reached 60-70% confluency, media was replaced by DMEM plus 1mM glutamine, and cells transfected with WT-Htt and polyQ-Htt constructs (1-

969)<sup>29</sup> using Lipofectamine 2000 (Invitrogen), as previously described<sup>39</sup>. JNK activation was evaluated 24h after transfection.

**Microtubule-binding Assays:** NSC34 cells were transfected with WT-Htt and polyQ-Htt constructs as described above. After 24 hours, cells were scraped in BRB80 buffer [80 mM PIPES pH 7, 1 mM MgCl<sub>2</sub>, 1 mM EGTA, 1  $\mu$ M staurosporine, 1  $\mu$ M K252a, 50 nM okadaic acid, 200 nM microcystin, 1/100 dilution of phosphatase inhibitor cocktail II (Calbiochem), and 1/100 dilution of mammalian protease inhibitor cocktail (Sigma)] at 4°C, and homogenized using a 30g syringe (500 $\mu$ l of BRB80/10 cm dish). Lysates were centrifuged at 14,000 rpm in a tabletop centrifuge for 5 minutes, and centrifuged at 55,000 rpm in TLA100.3 rotor for additional 5 minutes. 700  $\mu$ g of total protein from clarified supernatants were incubated with 0.2 mg of taxol-stabilized microtubules and 2.5 mM AMP-PNP (Sigma) for 30 min at 37 °C. The mixture above was loaded on top of a cushion made of 20% sucrose in BRB80 buffer, and centrifuged for 15 minutes at 50,000 rpm using a Beckman TLA-100.3 rotor at room temperature. Microtubule-enriched pellets were resuspended in Laemmli buffer and analyzed by immunoblotting. For microtubule binding experiments (**Fig. 7B**), 4 $\mu$ l aliquots of *in vitro*-phosphorylated KHC<sup>584</sup> (prepared as above) were incubated with 64 $\mu$ g of taxol-stabilized microtubules in BRB80 buffer and either 2mM AMP-PNP or 2mM ATP (100 $\mu$ l total volume). After 30 minutes incubation, these mixtures were centrifuged for 15 minutes at 50,000 rpm over a cushion of 20% in BRB80 in a Beckman TLA-100.3 rotor at 37° C. Pellets and supernatants were collected, and the levels of kinesin in each fraction quantified by phosphorimager scanning of radioactivity or with fluorescently-labeled secondary antibodies.

**Kinesin-1 Translocation Assays:** Accumulation of KHC<sup>560</sup>-GFP-WT and KHC<sup>560</sup>-GFP-S176E constructs in neurites of cultured hippocampal neurons was evaluated as before<sup>37</sup>.

**Statistical Analysis.** All experiments were repeated at least 3 times. Unless otherwise stated, the data was analyzed by ANOVA followed by post-hoc Student-Newman-Keul's test in order to make

all possible comparisons. Data was expressed as mean  $\pm$  SEM and significance was assessed at  $p < 0.05$  or  $0.01$  as noted.

**Mouse Brain Fractionation:** Brains from wild-type (12 months old) and Hdh<sup>Q109</sup> knock-in (14 months old) were homogenized in 3mls of HB buffer (50mM Hepes pH 7.4, 150 mM NaCl, 1% Triton X-100) and centrifuged 2X 2,500g for 10 minutes, and 1X at 7,000g for 10 minutes to pellet debris and nuclei. Clarified lysates were spun at 150,000g for 20 minutes, in a Beckman TLA 100.3 rotor at 55,000 RPM. The pellets and supernatant represented detergent insoluble and detergent-soluble fractions, respectively. Detergent insoluble pellets were resuspended in HB. Equal amounts of protein from each fraction were analyzed by immunoblotting.

**In vitro Phosphorylation:** *In vitro* phosphorylation experiments (40  $\mu$ l volume) were performed by incubating KHC<sup>584</sup> protein constructs (3  $\mu$ M) with 0.1 $\mu$ M JNK3 (Upstate) or 0.2 $\mu$ M JNK1 (Upstate) in HEM buffer (50 mM HEPES, 12 mM MgSO<sub>4</sub>, 100  $\mu$ M ATP pH 7.4), as previously described<sup>7</sup>.

**Mass Spectrometry Studies:** Phosphorylated KHC<sup>584</sup> protein was subjected to *in solution* trypsin digestion. Briefly, dried samples were resuspended in 30 mM Hepes, 30 mM NaF in the presence of 1  $\mu$ g of trypsin (Sigma, proteomics grade) and incubated at 37° C overnight (16-18h). The resulting tryptic peptides were later resuspended in buffer A (5% acetonitrile, 0.4% acetic acid, 0.005% of HFBA in water) for mass spectrometry analysis or prepared for IMAC<sup>35</sup>. Samples were analyzed by liquid chromatography on line with a LTQ (a two-dimensional ion trap) instrument equipped with a commercial nanospray source (Thermo Finnigan, San Jose, CA). Samples were automatically loaded by a microautosampler (Famos, LC Packings, Sunnyvale, CA) onto an 11-cm x 100 $\mu$ m fused silica capillary column packed with reverse C18 material (5- $\mu$ m, 100-Å Magic beads, Michrom Bioresources, Auburn, CA). The solvent system was delivered by an HP1100 pump (Agilent Technologies, Palo Alto, CA). Samples were analyzed by performing full scan followed by tandem MS or MS/MS or MS<sup>2</sup> of the 5 most intense ions (top 5) by collision induced dissociation

(CID). Sample loading, solvent delivery, and scan function were controlled with Xcalibur software (Thermo Finnigan). Liquid chromatography tandem mass spectrometry files were searched using SEQUEST algorithm against a generated database containing KIF5C\_Rat and KIF5C\_Mouse, among others proteins. SEQUEST search parameters included mass tolerance of  $\pm 1.5$  Da, trypsin specificity, and differential search for serine, threonine and tyrosine phosphorylation. The generated data set was filtered using INTERACT<sup>50</sup> based on the following criteria: delta correlation, dCn: 0.1, X correlation value for +1 peptides  $\geq 1.8$ , +2  $\geq 2.2$  and +3  $\geq 3.2$ .

### Bibliography

1. Okun, M.S. Huntington's disease: what we learned from the original essay. *Neurologist* **9**, 175-179 (2003).
2. Orr, H.T. & Zoghbi, H.Y. Trinucleotide repeat disorders. *Annu Rev Neurosci* **30**, 575-621 (2007).
3. Morfini, G., Pigino, G. & Brady, S.T. Polyglutamine Expansion Diseases: Failing to Deliver. *Trends Molec. Med.* **11**, 64-70 (2005).
4. Gunawardena, S., *et al.* Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. *Neuron* **40**, 25-40 (2003).
5. Lee, W.C., Yoshihara, M. & Littleton, J.T. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. *Proc Natl Acad Sci U S A* **101**, 3224-3229 (2004).
6. Trushina, E., *et al.* Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. *Mol Cell Biol* **24**, 8195-8209 (2004).
7. Morfini, G., *et al.* JNK Mediates Pathogenic Effects of Polyglutamine-expanded Androgen Receptor on Fast Axonal Transport. *Nat Neurosci* **9**, 907-916 (2006).
8. Szebenyi, G., *et al.* Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport. *Neuron* **40**, 41-52 (2003).
9. Colin, E., *et al.* Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. *Embo J* **27**, 2124-2134 (2008).
10. Gauthier, L.R., *et al.* Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. *Cell* **118**, 127-138 (2004).
11. Engelender, S., *et al.* Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. *Hum Mol Genet* **6**, 2205-2212 (1997).
12. Caviston, J.P., Ross, J.L., Antony, S.M., Tokito, M. & Holzbaur, E.L. Huntingtin facilitates dynein/dynactin-mediated vesicle transport. *Proc Natl Acad Sci U S A* **104**, 10045-10050 (2007).
13. Deboer, S.R., *et al.* Conventional Kinesin Holoenzymes Are Composed of Heavy and Light Chain Homodimers. *Biochemistry* **47**, 4535-4543 (2008).
14. Lazarov, O., *et al.* Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. *Journal of Neuroscience* **25**, 2386-2395 (2005).

15. Wheeler, V.C., *et al.* Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. *Hum. Molec. Genet.* **9**, 503-513 (2000).
16. Brill, L.B., 2nd & Pfister, K.K. Biochemical and molecular analysis of the mammalian cytoplasmic dynein intermediate chain. *Methods* **22**, 307-316 (2000).
17. Brady, S.T., Pfister, K.K. & Bloom, G.S. A monoclonal antibody against kinesin inhibits both anterograde and retrograde fast axonal transport in squid axoplasm. *Proc. Nat. Acad. Sci. USA* **87**, 1061-1065 (1990).
18. Morfini, G., Szebenyi, G., Elluru, R., Ratner, N. & Brady, S.T. Glycogen Synthase Kinase 3 Phosphorylates Kinesin Light Chains and Negatively Regulates Kinesin-based Motility. *EMBO Journal* **23**, 281-293 (2002).
19. Donelan, M.J., *et al.* Ca<sup>2+</sup>-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. *J Biol Chem* **277**, 24232-24242 (2002).
20. Apostol, B.L., *et al.* Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. *Hum Mol Genet* **15**, 273-285 (2006).
21. Merienne, K., Helmlinger, D., Perkin, G.R., Devys, D. & Trotter, Y. Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. *J Biol Chem* **278**, 16957-16967 (2003).
22. Liu, Y.F. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. *J. Biol. Chem.* **273**, 28873-28877 (1998).
23. Coffey, E.T., *et al.* c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. *J Neurosci* **22**, 4335-4345 (2002).
24. Fabian, M.A., *et al.* A small molecule-kinase interaction map for clinical kinase inhibitors. *Nat Biotechnol* **23**, 329-336 (2005).
25. Barr, R.K., Kendrick, T.S. & Bogoyevitch, M.A. Identification of the critical features of a small peptide inhibitor of JNK activity. *J Biol Chem* **277**, 10987-10997 (2002).
26. Dompierre, J.P., *et al.* Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. *J Neurosci* **27**, 3571-3583 (2007).
27. Kozikowski, A.P., *et al.* Functional Differences in Epigenetic Modulators-Superiority of Mercaptoacetamide-Based Histone Deacetylase Inhibitors Relative to Hydroxamates in Cortical Neuron Neuroprotection Studies. *J Med Chem* **50**, 3054-3061 (2007).
28. Gallo, K.A. & Johnson, G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. *Nat Rev Mol Cell Biol* **3**, 663-672 (2002).
29. Qin, Z.H., *et al.* Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. *J Neurosci* **24**, 269-281 (2004).
30. Bjorkblom, B., *et al.* All JNKs Can Kill, but Nuclear Localization Is Critical for Neuronal Death. *J Biol Chem* **283**, 19704-19713 (2008).
31. Nishitoh, H., *et al.* ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. *Genes Dev* **16**, 1345-1355 (2002).
32. Coffey, E.T., Hongisto, V., Dickens, M., Davis, R.J. & Courtney, M.J. Dual roles for c-Jun N-terminal kinase in developmental and stress responses in cerebellar granule neurons. *J Neurosci* **20**, 7602-7613 (2000).

33. Thomas, G.M., Lin, D.T., Nuriya, M. & Huganir, R.L. Rapid and bi-directional regulation of AMPA receptor phosphorylation and trafficking by JNK. *EMBO J* **27**, 361-372 (2008).
34. Ito, M., *et al.* Isoforms of JSAP1 scaffold protein generated through alternative splicing. *Gene* **255**, 229-234 (2000).
35. Nuhse, T.S., Stensballe, A., Jensen, O.N. & Peck, S.C. Large-scale analysis of in vivo phosphorylated membrane proteins by immobilized metal ion affinity chromatography and mass spectrometry. *Mol Cell Proteomics* **2**, 1234-1243 (2003).
36. Sack, S., *et al.* X-ray structure of motor and neck domains from rat brain kinesin. *Biochemistry* **36**, 16155-16165 (1997).
37. Jacobson, C., Schnapp, B. & Banker, G.A. A change in the selective translocation of the Kinesin-1 motor domain marks the initial specification of the axon. *Neuron* **49**, 797-804 (2006).
38. Lapointe, N.E., *et al.* The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications for filament toxicity. *J Neurosci Res* **87**, 440-451 (2009).
39. Pigino, G., Morfini, G., Mattson, M.P., Brady, S.T. & Busciglio, J. Alzheimer's Presenilin 1 Mutations Impair Kinesin-Based Axonal Transport. *J. Neurosci.* **23**, 4499-4508 (2003).
40. Roy, S., Zhang, B., Lee, V.M. & Trojanowski, J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. *Acta Neuropathol (Berl)* **109**, 5-13 (2005).
41. McGuire, J.R., Rong, J., Li, S.H. & Li, X.J. Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. *J Biol Chem* **281**, 3552-3559 (2006).
42. Li, H., Li, S.H., Yu, Z.X., Shelbourne, P. & Li, X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. *J Neurosci* **21**, 8473-8481 (2001).
43. Carmichael, J., Sugars, K.L., Bao, Y.P. & Rubinsztein, D.C. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. *J Biol Chem* **277**, 33791-33798 (2002).
44. Colin, E., *et al.* Akt is altered in an animal model of Huntington's disease and in patients. *Eur J Neurosci* **21**, 1478-1488 (2005).
45. Garcia, M., Charvin, D. & Caboche, J. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. *Neuroscience* **127**, 859-870 (2004).
46. Gupta, S., *et al.* Selective interaction of JNK protein kinase isoforms with transcription factors. *Embo J* **15**, 2760-2770 (1996).
47. Yang, D.D., *et al.* Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. *Nature* **389**, 865-870 (1997).
48. Bogoyevitch, M.A. & Kobe, B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. *Microbiol Mol Biol Rev* **70**, 1061-1095 (2006).
49. Cha, J.H. Transcriptional signatures in Huntington's disease. *Prog Neurobiol* **83**, 228-248 (2007).
50. Han, D.K., Eng, J., Zhou, H. & Aebersold, R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. *Nat Biotechnol* **19**, 946-951 (2001).